New data from Dexcom has demonstrated the benefit of its G7 continuous glucose monitor (CGM) in type 2 diabetes (TD2) patients not receiving insulin, suggesting a new standard of care (SoC) could be ushered in for this patient population.
The CONNECT randomised control trial of 265 evaluable patients assessed G7’s impact on blood glucose management and blood glucose (A1C) levels. At baseline, mean A1C was 8.8%, with 31% of participants having an A1C ≥9%.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patients assigned G7 experienced, on average, an A1C reduction of 1.6% at 26 weeks, indicative of a 0.9% greater A1C reduction versus the self-monitoring control group. For those with a higher initial A1C, the reduction was even greater.
Historically, CGMs have primarily been used by diabetes patients being treated with insulin. However, growing evidence – such as the results produced by the CONNECT trial – is demonstrating the technology’s benefit in wider patient groups.
For example, time in the target glucose target range of 70 to 180 mg/dL was five hours greater per day for participants using G7 versus the control group, with these improvements observable from 1-4 weeks and sustained through the 26-week data cutoff, Dexcom stated.
At the end of the 26-week period, patients using G7 achieved an average time in range of 62% compared with 41% in the control group.
Dexcom’s study also found that patients using G7 with various combinations of current SoC diabetes medication achieved clinically significant A1C reductions. Of the study’s enrolled patients, 37% were using an SGLT2 inhibitor, while 40% were using incretin-based medications such as glucagon-like peptide 1 receptor agonists (GLP-1RAs).
The study’s findings were presented at the 2026 American Diabetes Association’s (ADA) Scientific Sessions, held from 5-8 June in New Orleans, Louisiana.
Describing the CONNECT study’s findings as the “first and only level A evidence” demonstrating the benefit of CGM for the T2D non-insulin-using population, Roy Beck, medical director of the JAEB Center for Health Research and senior author of the study, commented that the results could drive “meaningful changes in standards of care.”
CONNECT is now undergoing a six-month extension phase to evaluate G7 in TD2 patients not on insulin for up to one year.
Commenting on the 26-week data, Dexcom CEO Jake Leach said: “We anticipate these results will help establish a new standard of care in the US and around the world.”
